Is the new Congress ready to lower drug costs?

With STAT’s Washington Correspondents, Lev Facher and Nicholas Florko
Agenda

1. The Midterms
2. The Trump Administration
3. Legislation to Watch
4. Investigations
5. Lobbying
The Midterms
GOP holds Senate, Dems gain 40 House seats

Senate Majority Leader Mitch McConnell (R-Ky.)
Speaker of the House Nancy Pelosi (D-Calif.)
The House Ways & Means Committee

Rep. Richard Neal (D-Mass.)

Rep. Lloyd Doggett (D-Texas)
The House Energy & Commerce Committee

Rep. Anna Eshoo (D-Calif.)

Rep. Frank Pallone (D-N.J.)
The House Energy & Commerce Committee

“We are going to do at least one diabetes hearing.”

Rep. Diana DeGette (D-Colo.)
The House Oversight Committee

**House Freedom Caucus**
- Jim Jordan
- Mark Meadows
- Justin Amash
- Paul Gosar
- Jody Hice
- Michael Cloud
- Ralph Norman
- Chip Roy
- Mark Green

**House Progressive Caucus**
- Elijah Cummings
- Carolyn Maloney
- Lacy Clay
- Jamie Raskin
- Katie Hill
- Peter Welch
- Mark DeSaulnier
- Brenda Lawrence
- Ro Khanna
- Jimmy Gomez
- Alexandria Ocasio-Cortez
- Ayanna Pressley
- Rashida Tlaib
Senate Finance Committee

Sen. Chuck Grassley (R-Iowa)

Sen. Ron Wyden (D-Ore.)
“This legislation is a significant step forward to fixing the problems in our health care system that have allowed pharmaceutical manufacturers to price gouge taxpayers and consumers for too long.”

—Sen. Grassley on the Right Rebate Act of 2018, co-sponsored with Wyden
The Senate HELP Committee

Sen. Lamar Alexander (R-Tenn.)

Sen. Mitt Romney (R-Utah)
The Senate Judiciary Committee
The Trump Administration
The White House

Joe Grogan, Chair, Domestic Policy Council
Former Head of Federal Affairs, Gilead

Shahira Knight, White House Director of Legislative Affairs
Legislation to Watch
Legislation that will be taken seriously

→ Reforms for Medicare Part D
→ CREATEES Act
→ Preserve Access to Affordable Generics Act
(Pay for Delay)
Messaging from 2020 candidates

→ Bernie Sanders’ international price index
→ Elizabeth Warren’s generic drug manufacturing bill
→ Klobuchar & Harris’ bill to block price increases
→ Various iterations of Medicare negotiation
→ Klobuchar, Brown & Harris’ drug exclusivity bill
Wild cards

→ Grassley-Klobuchar personal drug importation
→ PBM transparency bills
→ Cassidy-Warner value-based pricing bill
→ Wyden’s bill requiring justification for price spikes
→ Wyden-Grassley bill on Medicaid rebates
Investigations
Members & Companies Impacted

Senate Finance
AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., Pfizer, Sanofi, Eli Lilly, Novo Nordisk

House Oversight
AstraZeneca, Teva, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Amgen, Pfizer, Novo Nordisk, Sanofi, AbbVie

House Energy & Commerce
Sanofi, Eli Lilly, Novo Nordisk
Lobbying
Other groups to watch
Q&A
Thanks!

@levfacher  @NicholasFlorko